Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS‐650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|2|4|316-327

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.2, Iss.4, 2013-10, pp. : 316-327

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 12, 2016-03 ,pp. : 1351-1361

Bentham Science Publishers

Access to resources Recommend Favorite

Hepatitis C NS3 protease inhibitors

By  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 5, 1999-05 ,pp. : 663-665

Informa Healthcare

Access to resources Recommend Favorite

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection

By Herbst D Alan   Reddy K Rajender  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite

Novel tripeptide inhibitors of hepatitis C virus NS3 serine protease

By  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 2, 2003-02 ,pp. : 267-272

Informa Healthcare

Access to resources Recommend Favorite

Discovery and Development of VX-950, a Novel, Covalent, and Reversible Inhibitor of Hepatitis C Virus NS3.4A Serine Protease

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 6, Iss. 1, 2006-03 ,pp. : 3-16

Bentham Science Publishers

Access to resources Recommend Favorite